Lung Cancer Trials Ask AI to find trials
RecruitingPhase 2NCT07218601
Official study title

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Study summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedBreath sample collection and Research blood collection

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 2
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Diagnostic Test: Breath sample collection; Diagnostic Test: Research blood collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Study topics
Before surgery (neoadjuvant)→After surgery (adjuvant)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age ≥18
  • Untreated clinical stage I NSCLC amenable to upfront surgery
  • Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery
  • ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 23, 2026. Always confirm current availability with the study team.

View original record ↗